Real-world data to reveal vaccine power against long COVID
NCT ID NCT05876377
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study uses anonymous health records from California and Louisiana to see how effective the Pfizer-BioNTech COVID-19 vaccine is at preventing post-COVID conditions (long COVID). Researchers will also look at who gets vaccinated. The study includes adults with a COVID-19 diagnosis between September 2024 and August 2025, and follows them for up to 180 days after infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.